Kura肿瘤学和Kyowa Kirin伙伴开发并销售一种新的血癌药物Ziftomenib。 Kura Oncology and Kyowa Kirin partner to develop and commercialize a new blood cancer drug, Ziftomenib.

Kura肿瘤学和Kyowa Kirin建立了全球伙伴关系,开发并商业化Ziftomenib,一种治疗急性流质白血病(AML)和其他血液癌的药物。 Kura Oncology and Kyowa Kirin have formed a global partnership to develop and commercialize Ziftomenib, a drug for treating acute myeloid leukemia (AML) and other blood cancers. 库拉将提前收到3.3亿美元和最高12亿美元的里程碑付款。 Kura will receive $330 million upfront and up to $1.2 billion in milestone payments. 这些公司将在美国平等分享利润,由Kura公司领导美国开发公司,Kyowa Kirin公司负责美国境外的商业化。 The companies will share profits equally in the U.S., with Kura leading U.S. development and Kyowa Kirin handling commercialization outside the U.S. 合作的目的是通过商业化推动药物的销售,并可能于2025年提交林业发展局批准。 The collaboration aims to advance the drug through commercialization and includes a potential submission for FDA approval in 2025.